We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

77 hedge funds and large institutions have $87.1M invested in Calithera Biosciences, Inc in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

492% more call options, than puts

Call options by funds: $71K | Put options by funds: $12K

5% less funds holding

Funds holding: 8177 (-4)

17% less capital invested

Capital invested by funds: $105M → $87.1M (-$17.8M)

17% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 29

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

Holders
77
Holders Change
-4
Holders Change %
-4.94%
% of All Funds
1.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
24
Reduced
29
Closed
11
Calls
$71K
Puts
$12K
Net Calls
+$59K
Net Calls Change
-$158K
Name Holding Trade Value Shares
Change
Change in
Stake
State Board of Administration of Florida Retirement System
51
State Board of Administration of Florida Retirement System
Florida
$61K
PPA
52
Parametric Portfolio Associates
Washington
$58K -$38.3K -388 -35%
California Public Employees Retirement System
53
California Public Employees Retirement System
California
$57K
Simplex Trading
54
Simplex Trading
Illinois
$53K +$65.9K +668 New
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$49K -$102K -1,030 -63%
VF
56
Virtu Financial
New York
$49K +$60.2K +610 New
Acadian Asset Management
57
Acadian Asset Management
Massachusetts
$48K -$179K -1,817 -75%
VOYA Investment Management
58
VOYA Investment Management
Georgia
$46K
MAM
59
Meeder Asset Management
Ohio
$38K +$41.7K +423 +863%
JP Morgan Chase
60
JP Morgan Chase
New York
$32K -$1.07M -10,892 -96%
ADL
61
Asset Dedication LLC
California
$24K -$35.5K -360 -55%
Legal & General Group
62
Legal & General Group
United Kingdom
$22K +$7.4K +75 +38%
AIP
63
Ameritas Investment Partners
Nebraska
$11K
AA
64
AlphaMark Advisors
Kentucky
$9K
BAM
65
Bruderman Asset Management
New York
$8K +$9.86K +100 New
BNP Paribas Financial Markets
66
BNP Paribas Financial Markets
France
$4.44K -$99 -1 -2%
TRCT
67
Tower Research Capital (TRC)
New York
$4K -$14.8K -150 -74%
IUHSA
68
Itau Unibanco Holding S.A.
Brazil
$4K -$1.48K -15 -21%
AG
69
Advisor Group
Arizona
$4K
PNC Financial Services Group
70
PNC Financial Services Group
Pennsylvania
$4K
Macquarie Group
71
Macquarie Group
Australia
$2K -$3.06K -31 -61%
Nisa Investment Advisors
72
Nisa Investment Advisors
Missouri
$2K
Bank of Montreal
73
Bank of Montreal
Ontario, Canada
$2K +$888 +9 +82%
Fidelity Investments
74
Fidelity Investments
Massachusetts
$1K -$986 -10 -50%
AWMS
75
Advocacy Wealth Management Services
Georgia
$1K

CALA Hedge Fund Activity: Q4 2018 in Review

77 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q4 2018, worth a combined $87.1M — down 17% from $105M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of CALA and 9 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 24 added.

The largest buyer was Federated Hermes, adding an estimated $8.18M. The largest seller was Man Group, cutting an estimated $1.79M.

  • 77 institutional investors held Calithera Biosciences, Inc (CALA) as of Q4 2018, down from 81 in Q3 2018.
  • Funds reported $87.1M of Calithera Biosciences, Inc stock for Q4 2018, down 17% quarter-over-quarter.
  • 9 funds opened new Calithera Biosciences, Inc positions in Q4 2018 and 11 closed out, a net change of -2 holders.
  • The largest Calithera Biosciences, Inc buyer in Q4 2018 was Federated Hermes, an estimated $8.18M added.
  • The largest Calithera Biosciences, Inc seller in Q4 2018 was Man Group, an estimated $1.79M sold.

Based on aggregated 13F filings for Q4 2018.